ELV

Elevance HealthNYSE · Managed Health Care · Health Care

Previous close

412.56

Change

−4.98 / −1.19%

FinDog View

Neutral

52-Week Range

274.84 – 436.24

P/E (TTM)

18.2

Forward P/E

13.2

Based on consensus earnings for the next 12 months

Market Cap

$89.5B

+5.72%

S&P 500 −2.41% over same period

Volume / Avg Volume

1.1M / 1.3M

0.88× average

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 16.51M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q2 Quarter ended 2026-06	2026-07-15	$50.5B	7.45 / 6.27	−4.48%	Pending
FY2026 Q1 Quarter ended 2026-03	2026-04-22	$50.2B	12.58 / 10.93	+5.51%	Pending
FY2025 Q4 Quarter ended 2025-12	2026-01-28	—	— / —	+1.50%	Pending
FY2025 Q3 Quarter ended 2025-09	2025-10-21	—	— / —	−1.30%	Pending
FY2025 Q2 Quarter ended 2025-06	2025-07-17	—	— / —	−8.38%	Pending
FY2025 Q1 Quarter ended 2025-03	2025-04-22	—	— / —	+2.64%	Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 71 of its 5-year rangeExpensive

5-year range 11.7 – 20.4 · Median 16.5

Last 4 quarters: $2.7B in buybacks + $1.5B in dividends, 4.70% of market cap combined

P/E (TTM)

18.2

P/B

2.0

P/S

0.5

Dividend Yield

1.24%

Earnings Reaction

Over the last 6 reports, the stock moved ±4.0% on average on the first trading day after, rising 3 times

Most recent −4.48%

Volatility & Correlation

1-year beta 0.34 · Correlation with S&P 500 0.12Low beta

Annualized volatility 35% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 2 · $1.4MSell 0 · $0.00MNet buying $1.4M

07-17BOUDREAUX GAILPresident and CEOBuy$1.0M2,725 shares · 2 trades · Avg price 367.79
07-17PERU RAMIRO GDirectorBuy$0.37M1,000 shares · Avg price 366.05

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q2	50.47	+1.4%	89.1%	1.76	1.46	1.63	6.71
FY2026 Q1	50.18	+2.6%	89.1%	2.09	1.76	4.10	8.00
FY2025 Q4	49.75	+9.5%	88.9%	0.31	0.55	-0.21	2.56
FY2025 Q3	50.71	+12.4%	89.4%	1.30	1.19	0.78	5.32
FY2025 Q2	49.78	+13.4%	89.4%	2.43	1.74	1.79	7.72
FY2025 Q1	48.89	+14.8%	89.8%	3.17	2.18	0.82	9.61
FY2024 Q4	45.44	+6.6%	86.8%	0.67	0.42	0.38	1.88
FY2024 Q3	45.11	+5.3%	88.7%	1.41	1.02	2.35	4.36
FY2024 Q2	43.89	+0.5%	89.0%	2.77	2.30	0.12	9.85
FY2024 Q1	42.58	+1.0%	91.0%	3.02	2.25	1.70	9.59
FY2023 Q4	42.65	+6.8%	88.7%	1.28	0.86	-3.30	3.68
FY2023 Q3	42.85	+7.3%	89.2%	1.76	1.29	2.29	5.45

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
ELV	Elevance Health	$89.5B	18.2	+1.4%	89.1%	+5.72%	Neutral
LLY	Lilly (Eli)	$1.07T	39.9	+47.7%	85.8%	−3.83%	Bullish	Compare
JNJ	Johnson & Johnson	$644B	30.6	+6.6%	68.2%	+1.87%	Bullish	Compare
ABBV	AbbVie	$464B	73.7	+10.2%	74.7%	+4.87%	Neutral	Compare
MRK	Merck & Co.	$358B	112.2	+5.1%	73.5%	+6.57%	Neutral	Compare
UNH	UnitedHealth Group	$337B	23.9	+0.4%	88.1%	−5.15%	Neutral	Compare
TMO	Thermo Fisher Scientific	$240B	34.4	+10.5%	—	+10.75%	Bullish	Compare
AMGN	Amgen	$203B	23.3	+9.5%	72.0%	−10.26%	Neutral	Compare
GILD	Gilead Sciences	$183B	—	+10.2%	79.8%	+6.31%	Neutral	Compare